Emergent BioSolutions Inc., maker of J&J vaccine, sued by investors over tainted doses

Emergent BioSolutions Inc. allegedly failed to tell investors about manufacturing issues at its Baltimore plant that led to the contamination of up to 15 million Johnson & Johnson coronavirus vaccine doses, a suit says in federal court in Maryland. The biopharmaceutical company touted deals to produce vaccines for J&J and AstraZeneca, but didn’t disclose a history of manufacturing problems at the plant that increased the likelihood of “massive contaminations,” investors told the U.S. District Court for the District of Maryland.